{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:09:18Z","timestamp":1780643358601,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jacl.2025.03.015","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T01:07:48Z","timestamp":1743469668000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-0883","authenticated-orcid":false,"given":"Marcello","family":"Arca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4667","authenticated-orcid":false,"given":"Laura","family":"D'Erasmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-3824","authenticated-orcid":false,"given":"Marina","family":"Cuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-5912","authenticated-orcid":false,"given":"Dirk","family":"J. Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimini","family":"Cegla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5154","authenticated-orcid":false,"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallyann","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.03.015_bib0001","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.03.015_bib0002","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.03.015_bib0003","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s12325-021-01720-y","article-title":"Homozygous familial hypercholesterolemia (HoFH) in Saudi Arabia and two cases of lomitapide use in a real-world setting","volume":"38","author":"Mahzari","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2025.03.015_bib0004","first-page":"147","article-title":"Genetic screening for homozygous and heterozygous familial hypercholesterolemia","volume":"3","author":"Izar","year":"2010","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.jacl.2025.03.015_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cjco.2020.01.003","article-title":"Familial hypercholesterolemia and the founder effect among Franco-Americans: a brief history and call to action","volume":"2","author":"Mszar","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.jacl.2025.03.015_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000664","article-title":"Autosomal recessive hypercholesterolemia: update for 2020","volume":"31","author":"D'Erasmo","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0008","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCULATIONAHA.123.067241","article-title":"LDL-C-lowering therapies for adults and children with homozygous familial hypercholesterolemia: challenges and successes","volume":"149","author":"Santos","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.03.015_bib0009","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.03.015_bib0010","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.03.015_bib0011","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jacl.2025.03.015_bib0012","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.03.015_bib0013","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.03.015_bib0014","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.03.015_bib0015","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","article-title":"New algorithms for treating homozygous familial hypercholesterolemia","volume":"33","author":"Tromp","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/ph16010064","article-title":"Current treatment options in homozygous familial hypercholesterolemia","volume":"16","author":"Kayikcioglu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacl.2025.03.015_bib0017","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.03.015_bib0018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term Evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0019","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11883-021-00972-x","article-title":"Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9 and ANGPTL3 inhibitors","volume":"23","author":"Pirillo","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2025.03.015_bib0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jacl.2021.11.014","article-title":"Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis","volume":"16","author":"Alothman","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0021","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: A scientific statement from the American heart association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thrombosis Vasc Biol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0022","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0023","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0024","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00041433-199706000-00002","article-title":"Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly","volume":"8","author":"Gordon","year":"1997","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0029","article-title":"Intensive combination LDL-lowering therapy in a patient with homozygous familial hypercholesterolemia","volume":"29","author":"Tada","year":"2024","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jacl.2025.03.015_bib0030","first-page":"832","article-title":"Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry","volume":"29","author":"D'Erasmo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2025.03.015_bib0031","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/1744-9987.13856","article-title":"Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia","volume":"26","author":"Duell","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jacl.2025.03.015_bib0032","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.03.015_bib0033","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/eurjpc\/zwae144","article-title":"Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0034","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.03.015_bib0036","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2015.03.014","article-title":"The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a phase 3, single-arm, open-label trial","volume":"240","author":"Stefanutti","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.03.015_bib0037","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.03.015_bib0038","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5551\/jat.38216","article-title":"Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia","volume":"24","author":"Harada-Shiba","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2025.03.015_bib0039","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0040","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy","volume":"34","author":"D'Erasmo","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2025.03.015_bib0041","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","article-title":"Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey","volume":"16","author":"D'Erasmo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacl.2025.03.015_bib0042","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0043","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s12325-019-00985-8","article-title":"Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia","volume":"36","author":"Ben-Omran","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2025.03.015_bib0044","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2047487319870007","article-title":"Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia","volume":"27","author":"Kolovou","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2020.07.028","article-title":"Lomitapide for treatment of homozygous familial hypercholesterolemia: the Qu\u00e9bec experience","volume":"310","author":"Aljenedil","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.03.015_bib0046","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurjpc\/zwae036","article-title":"Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry","volume":"31","author":"D'Erasmo","year":"2024","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0047","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s12325-021-02031-y","article-title":"A case series assessing the effects of lomitapide on carotid intima-media thickness in adult patients with homozygous familial hypercholesterolaemia in a real-world setting","volume":"39","author":"Blom","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2025.03.015_bib0048","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13023-024-03374-9","article-title":"Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series","volume":"19","author":"Suppressa","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacl.2025.03.015_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1515846","article-title":"New insights into the management of homozygous familial hypercholesterolemia patients treated with lomitapide: a single-center experience","volume":"15","author":"Iannuzzo","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0050","doi-asserted-by":"crossref","first-page":"118517","DOI":"10.1016\/j.atherosclerosis.2024.118517","article-title":"The long-term, real-world effectiveness and safety of lomitapide in homozygous familial hypercholesterolaemia (HoFH): nine-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"395","author":"Blom","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.03.015_bib0051","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jacl.2025.03.015_bib0052","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacl.2019.03.001","article-title":"Case report: the efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child","volume":"13","author":"Chacra","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0053","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccas.2019.06.029","article-title":"Xanthomas regression in an 8-year-old boy treated with lomitapide","volume":"1","author":"Kolovou","year":"2019","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jacl.2025.03.015_bib0054","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/2047487317730473","article-title":"The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis","volume":"24","author":"Leipold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0055","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.jval.2018.09.552","article-title":"Real-world LDL-C changes experienced with lomitapide modelled to potentially increase life-expectancy in homozygous familial hypercholesterolemia (HoFH)","volume":"21","author":"Ager","year":"2018","journal-title":"Value in Health"},{"key":"10.1016\/j.jacl.2025.03.015_bib0057","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13244-020-00919-x","article-title":"Position statement and best practice recommendations on the imaging use of ultrasound from the European Society of Radiology ultrasound subcommittee","volume":"11","year":"2020","journal-title":"Insights Imaging"},{"key":"10.1016\/j.jacl.2025.03.015_bib0058","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36:100780","author":"Anstee","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jacl.2025.03.015_bib0059","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.23.29437","article-title":"MR elastography: practical questions, from the AJR special series on imaging of fibrosis","volume":"222","author":"Yin","year":"2024","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","article-title":"FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice","volume":"13","author":"Tapper","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0061","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0062","doi-asserted-by":"crossref","first-page":"e2008","DOI":"10.1210\/clinem\/dgab933","article-title":"Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease","volume":"107","author":"Qadri","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.015_bib0063","series-title":"Lomitapide (Juxtapid) [Internet]","year":"2015"},{"key":"10.1016\/j.jacl.2025.03.015_bib0064","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacl.2023.03.004","article-title":"Individualized dosing of evinacumab is predicted to yield reductions in drug expenses","volume":"17","author":"Ter Heine","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.015_bib0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T01:17:37Z","timestamp":1749863857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":60,"alternative-id":["S1933287425000686"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.015","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}